Preventive effects of sequential treatment with alendronate and 1 alpha-hydroxyvitamin D3 on bone mass and strength in ovariectomized rats (Q44550178)

4 December 2017

title

Preventive effects of sequential treatment with alendronate and 1 alpha-hydroxyvitamin D3 on bone mass and strength in ovariectomized rats (English)

1 reference

4 December 2017

Ito M

1

1 reference

4 December 2017

Azuma Y

2

1 reference

4 December 2017

Takagi H

3

1 reference

4 December 2017

Kamimura T

4

1 reference

4 December 2017

Komoriya K

5

1 reference

4 December 2017

Ohta T

6

1 reference

4 December 2017

Kawaguchi H

7

1 reference

4 December 2017

publication date

1 July 2003

1 reference

4 December 2017

1 reference

4 December 2017

volume

33

1 reference

4 December 2017

issue

1

1 reference

4 December 2017

page(s)

90-99

1 reference

Postmenopausal osteoporosis.

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Human osteoclast formation and activity in vitro: effects of alendronate.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Rationale for the use of alendronate in osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Calcium supplementation and bone loss: a review of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Vitamin D for the treatment of osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

1,25-Dihydroxyvitamin D3 in the pathogenesis and treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Treatment of postmenopausal osteoporosis with calcitriol or calcium

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

The development of vitamin D3 analogues for the treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Is there a differential response to alfacalcidol and vitamin D in the treatment of osteoporosis?

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Vitamin D in the treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

1,25-Dihydroxyvitamin D3: short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Additive effects of combined treatment with etidronate and alfacalcidol on bone mass and mechanical properties in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Curative effect of combined treatment with alendronate and 1 alpha-hydroxyvitamin D3 on bone loss by ovariectomy in aged rats

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Ethical guidelines for investigations of experimental pain in conscious animals

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Measurement of intact rat osteocalcin in osteoblast (ROS17/2.8) cells and in ovariectomized rats with a sandwich enzyme immunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Sequential and precise in vivo measurement of bone mineral density in rats using dual-energy x-ray absorptiometry

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

The effect of aging and ovariectomy on the vertebral bone mass and biomechanical properties of mature rats

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Compressive strength, ash weight, and volume of vertebral trabecular bone in experimental fluorosis in pigs

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84).

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Low-intensity pulsed ultrasound accelerates rat femoral fracture healing by acting on the various cellular reactions in the fracture callus

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

On the absorption of alendronate in rats

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Skeletal effects of constant and terminated use of risedronate on cortical bone in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Evaluation of long-term sequential changes in bone mass and strength following withdrawal of incadronate disodium (YM175) in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Long-term effects of withdrawal of bisphosphonate incadronate disodium (YM175) on bone mineral density, mass, structure, and turnover in the lumbar vertebrae of ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Bone matters: are density increases necessary to reduce fracture risk?

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Relationship of bone turnover to bone density and fractures

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900170-4

7 January 2021

10.1016/S8756-3282(03)00170-4

Identifiers

DOI

1 reference

4 December 2017

1 reference